Tracers / [177Lu]Lu-HTK03170

[177Lu]Lu-HTK03170

Also written as [Lu-177]Lu-HTK03170

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer PSMA-directed radioligand therapy

What it is

Compound class: PSMA-targeted radioligand (Lys-urea-Aad pharmacophore-derived, DOTA-conjugated)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 37649602
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC+SPE	10-49% yes	≥92%	HTK03170 (DOTA-conjugated precursor)	37649602 2023 Theranostics [177Lu]LuCl3 (~500 MBq in ~15 μL) was added to a solution of the DOTA-conjugated precursor (25 μg) in NaOAc buffer (0.5 mL, 0.1 M, pH 4.5). The mixture was incubated at 90 °C for 15 min — the desired 177Lu-labeled HTK03170, HTK04048 and HTK04028 were obtained in 10-49% decay-corrected radiochemical yields

Need this precursor?We can point you to suppliers for [177Lu]Lu-HTK03170, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37649602. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37649602: 'HTK03170 (DOTA-conjugated precursor)'.